Human Hepatic Hepa RG Cells Maintain an Organotypic Phenotype with High Intrinsic CYP 450 Activity/Metabolism and Significantly Outperform Standard HepG2/C3A Cells for Pharmaceutical and Therapeutic Applications
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Conventional in vitro human hepatic models for drug testing are based on the use of standard cell lines derived from hepatomas or primary human hepatocytes (PHH s). Limited availability, interdonor functional variability and early phenotypic alterations in PHH s restrict their use, whilst standard cell lines such as HepG2 lack a substantial and variable set of liver‐specific functions such as CYP 450 activity. Alternatives include the HepG2‐derivative C3A cells selected as a more differentiated and metabolically active hepatic phenotype. Human Hepa RG cells are an alternative organotypic co‐culture model of hepatocytes and cholangiocytes reported to maintain in vivo‐like liver‐specific functions, including intact Phase I–III drug metabolism. In this study, we compared C3A and human Hepa RG cells using phenotypic profiling, CYP 450 activity and drug metabolism parameters to assess their value as hepatic models for pre‐clinical drug testing or therapeutics. Compared with C3As, Hepa RG co‐cultures exhibit a more organotypic phenotype, including evidence of hepatic polarity with the strong expression of CYP 3A4, the major isoform involved in the metabolism of over 60% of marketed drugs. Significantly greater CYP 450 activity and expression of CYP 1A2, CYP 2E1 and CYP 3A4 genes in Hepa RG cells (comparable with that of human liver tissue) was demonstrated. Moreover, Hepa RG cells also preferentially expressed the hepatic integrin α 5 β 1 – an important modulator of cell behaviour including growth and survival, differentiation and polarity. Drug metabolite profiling of phenacetin (CYP 1A2) and testosterone (CYP 3A4) using LC‐MS/MS and HPLC, respectively, revealed that Hepa RG s had more intact (Phase I–II) metabolism profile. Thus, Hepa RG cells significantly outperform C3A cells for the potential pharmaceutical and therapeutic applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
Artificial liver: A forthcoming attraction
Sussman, N. L., & Kelly, J. H. (1993) · Hepatology · doi:10.1002/hep.1840170632 · Cited by 46
Cited by
Zhou, Y., Shen, J. X., & Lauschke, V. M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01093 · Cited by 85
“Compared to HepG2, HepaRG cells exhibit higher metabolic activity (Hart et al., 2010; Nelson et al., 2017; Yokoyama et al., 2018).”
Background3D human liver spheroids for translational pharmacology and toxicology
Ingelman‐Sundberg, M., & Lauschke, V. M. (2022) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13587 · Cited by 62
Kammerer, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910214 · Cited by 59
Liu, J., Li, R., Xue, R., Li, T., Leng, L., Wang, Y., Wang, J., Ma, J., Yan, J., Yan, F., et al. (2018) · Advanced Biosystems · doi:10.1002/adbi.201800110 · Cited by 23
Brovold, M., Keller, D., Devarasetty, M., Dominijanni, A., Shirwaiker, R., & Soker, S. (2021) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10207 · Cited by 11
Metadata
- Authors
- Nelson, L. J., Morgan, K., Treskes, P., Samuel, K., Henderson, C. J., LeBled, C., Homer, N., Grant, M. H., Hayes, P. C., & Plevris, J. N.
- Venue
- Basic & Clinical Pharmacology & Toxicology
- Publisher
- Wiley
- Published
- 2016-07-15
- Volume
- 120
- Issue
- 1
- Pages
- 30-37
- ISSN
- 1742-7835 (ISSN-L)
- 1742-7843
- OpenAlex
- W2413965588
- Cited by
- 73
- References
- 2
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Human Hepatic Hepa RG Cells Maintain an Organotypic Phenotype with High Intrinsic CYP 450 Activity/Metabolism and Significantly Outperform Standard HepG2/C3A Cells for Pharmaceutical and Therapeutic Applications. https://app.cochat.ai/papers/10.1111/bcpt.12631
- The paper
- Nelson, L. J., Morgan, K., Treskes, P., Samuel, K., Henderson, C. J., LeBled, C., Homer, N., Grant, M. H., Hayes, P. C., & Plevris, J. N. (2017). Human Hepatic Hepa RG Cells Maintain an Organotypic Phenotype with High Intrinsic CYP 450 Activity/Metabolism and Significantly Outperform Standard HepG2/C3A Cells for Pharmaceutical and Therapeutic Applications. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.12631
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.